Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Udenafil (Zydena®, Dong-A
Pharmaceutical co., Ltd, Seoul, Korea) in treatment of erectile dysfunction after radical
resection for sigmoid colon and rectal cancer. In this study, the efficacy of Udenafil will
be evaluated in treatment for patient with chronic erectile dysfunction, which developed
after radical resection for sigmoid and rectal cancer and continues 12 months after the
surgery.